The higher mut-KRAS frequency could be due to the fact that our cohort consisted solely of adenocarcinomas from Caucasian individuals treated with checkpoint inhibitor immunotherapy, thus excluding the patients with targetable mutations [27]. Here, KRAS is linked to adenocarcinoma.